Last edition
News about "Julio Chirinos"
Vasa Therapeutics Receives FDA IND Clearance to Advance Novel Small Molecule VS-041
Vasa Therapeutics plans to immediately initiate a phase-I (c) clinical trial in the US for participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
<br />
Julio Chirinos | 15/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members